Photo from archive.org
My recent report (Saavedra, 2020a) warned about the danger of removing ARBs from patients suffering from COVID-19 comorbidities, calling for definitive data analysis to determine whether ARB administration benefited COVID-19… Click to show full abstract
My recent report (Saavedra, 2020a) warned about the danger of removing ARBs from patients suffering from COVID-19 comorbidities, calling for definitive data analysis to determine whether ARB administration benefited COVID-19 patients. Huang and colleagues disagreed with my proposal. Based on preliminary information, they believed ARBs could not benefit COVID-19 patients and that increase in RAS activity was a simple concomitant symptom of COVID-19 with no bearing on the disease outcome. Here we report a summary of the evidence on the protective effects of ARBs on COVID-19 comorbidities and lung function, and the multiple ongoing clinical studies to determine the effect of ARBs on COVID-19 patients.
Journal Title: Pharmacological Research
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!